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Abstract
Objectives Older patients are particularly vulnerable to
hypoglycaemia. The aim of this study was to evaluate the
response to initiation of once-daily insulin detemir in
patients aged C75 years with type 2 diabetes mellitus
(T2DM) treated with one or more oral antidiabetic drugs
(OADs).
Methods A sub-analysis was conducted using data from
SOLVE (Study of Once daily LeVEmir), a 24-week
observational study involving 3,219 investigators and
2,817 project sites from ten countries. Routine clinical
practice was followed; there were no study-prescribed
procedures. The total cohort comprised 17,374 participants,
of whom 2,398 (14 %) were aged C75 years. The physi-
cians collected information from patient recall, the
patients’ medical records and their self-monitored blood
glucose diaries (if kept).
Results Pre-insulin glycated haemoglobin (HbA1c) was
similar between participants aged C75 years and those
aged \75 years (HbA1c 8.8 ± 1.5 % vs. 8.9 ± 1.6 %
[mean ± SD], respectively). After 24 weeks of treatment,
similar reductions in HbA1c were observed in the two
subgroups: 7.6 ± 1.1 % and 7.5 ± 1.2 % in participants
aged C75 years and those aged \75 years, respectively.
The incidence of severe hypoglycaemia (episodes per
patient-year) decreased during the study in both age groups
(from 0.057 to 0.007 in patients aged C75 years; from
0.042 to 0.005 in patients aged \75 years), while minor
hypoglycaemia increased from 1.1 to 2.0 and from 1.7 to
1.8 episodes per patient-year in the older and younger age
groups, respectively. Average weight reduction was
similar in both groups: -0.5 kg (C75 years) and -0.6 kg
(\75 years).
Conclusion In both the older and younger age groups, the
addition of once-daily insulin detemir to existing OAD
regimens was effective and safe. In older patients, an
improvement in HbA1c of 1.2 % was not associated with an
increased risk of severe hypoglycaemia or weight gain.
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1 Introduction
The difficulties in managing type 2 diabetes mellitus
(T2DM) in the elderly are myriad. Factors to consider in
relation to advancing age that influence treatment decisions
include co-morbidity, polypharmacy, visual and cognitive
impairment, severity of vascular complications, psychoso-
cial limitations, renal insufficiency, an increased risk of
falling, and a limited life expectancy [1, 2]. These con-
siderations are in addition to the regular management
principles of diabetes—those with the overall aim of
achieving good glycaemic control [3].
Diabetes mellitus is a common metabolic problem
affecting an estimated 336 million people worldwide [4].
Of people aged C25 years, the 2008 prevalence was
thought to be approximately 10 % [5]. This rate is
increasing. Improvements in cardiovascular risk factors
and the management of diabetic complications have con-
tributed to the increasing longevity of people living with
diabetes, which in turn has led to the increase in preva-
lence. In 2011, an estimated 25.8 million people of all ages
in the USA had diabetes. In people aged over 65 years,
26.9 % had diabetes, representing 10.9 million people and
over 40 % of the total number of people with diabetes in
the USA [6]. Globally, the current largest cohort living
with diabetes is the 40–59-years age group, but by 2030,
the 60–79-years age group is expected to supersede them,
with 196 million people affected [7]. Most patients with
diabetes over 65 years of age are presently between the
ages of 65 and 75 years; however, there will continue to be
a shift in demography over the coming decades, so that the
majority of the elderly population with diabetes will be
C75 years of age [8].
The annual global costs of the disease burden of diabetes
mellitus are thought to have been in the range of US$465
billion in 2011. By 2030, this cost is predicted to rise to
US$595 billion [9]. The average per-person healthcare
expenditure of people with diabetes in the USA is 2.3 times
that of those without the disease, [10] with three-quarters of
global healthcare spending on diabetes involving people
aged 50–70 years [9]. Furthermore, elderly patients have a
higher rate of diabetes-related hospitalizations compared
with younger patients with diabetes. The former are
responsible for 65.1 % of all diabetes-related healthcare
costs compared with 34.8 % for patients \65 years of age
in the USA [11].
In managing people with T2DM, as glycaemic targets
are approached, the risk of hypoglycaemia increases. The
risk of hypoglycaemia is even higher in the elderly because
of age-related complications, including co-morbidity, renal
impairment, drug–drug interactions, irregular meal pat-
terns, and poor self-monitoring of blood glucose [1, 12].
The risk of serious morbidity as a result of hypoglycaemia
is higher in this elderly cohort [1], and may include cardiac
ischaemia [13] and an increased risk of falling [14–16]. In
addition, as a result of longer duration of diabetes, older
people with diabetes may be at increased risk of developing
hypoglycaemic unawareness [17].
In absolute terms, although severe hypoglycaemia
remains a rare event, the rate increases rapidly amongst
certain groups. These include very elderly persons with co-
morbid conditions, those who are unaware of hypogly-
caemic symptoms, and those on insulin therapy [18]. It has
been shown that hypoglycaemia in the elderly with T2DM
is common [19], but actual rates may be higher than
reported [20]. Currently, there is also a paucity of data on
the pharmacological treatment of T2DM in the elderly
[21].
The purpose of this sub-analysis is to evaluate the
response to once-daily insulin detemir in patients aged
75 years or above, compared with those aged below
75 years, using data from SOLVE (Study of Once Daily
LeVEmir), which included a large number of older people.
The primary objective of the overall SOLVE study was to
assess the incidence of serious adverse drug reactions
(SADRs), including severe hypoglycaemic events, during
24 weeks in patients initiating once-daily treatment with
insulin detemir in real-life clinical practice.
2 Methods
SOLVE was a multinational, open-label observational
study of patients with T2DM treated with one or more oral
antidiabetic drugs (OADs) initiating insulin detemir treat-
ment. The study involved 3,219 investigators and 2,817
project sites from ten countries: Canada, China, Germany,
Israel, Italy, Poland, Portugal, Spain, Turkey and the UK.
The study duration was 24 weeks, and data were col-
lected on each patient during three routinely scheduled
clinic visits (baseline, interim and final) approximately
12 weeks apart. Data were collected during the period 4
February 2008 (first patient’s first visit) to 28 March 2011
(last patient’s last visit).
2.1 Measurements
In addition to the primary objective of measuring the
incidence of SADRs and severe hypoglycaemia during
24 weeks of once-daily basal insulin treatment, secondary
endpoints included glycated haemoglobin (HbA1c), mean
and variability of fasting plasma glucose (FPG), 7-point
blood glucose profile (self-monitored), full lipid profile,
and proportion of patients using anti-hypertensive and
lipid-lowering drugs. Information on insulin dose, minor
and nocturnal hypoglycaemic episodes, non-SADRs,
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weight, body mass index (BMI), waist and hip circumfer-
ence, and blood pressure were also recorded.
Minor hypoglycaemia was defined as a blood glucose
measurement of \3.1 mmol/L (\56 mg/dL) with or with-
out symptoms; a severe hypoglycaemic event was defined
as an event requiring third-party assistance; and a nocturnal
hypoglycaemic event was defined as any episode occurring
between bedtime and awakening the next morning. Minor
hypoglycaemic events were recorded as events recalled
within the preceding 4 weeks, and severe hypoglycaemic
events were recorded as events recalled within the pre-
ceding 12 weeks in all countries except the UK, where a
recall period of 4 weeks was used. The same definitions of
hypoglycaemia were used at all time points (i.e. pre-insu-
lin, interim and final visits).
The full analysis set comprised all enrolled patients
prescribed basal insulin at baseline. The effectiveness
analysis set comprised all patients from the full analysis set
with a final visit between 16 and 32 weeks, and at least one
measurement of FPG, HbA1c, or weight or record of
hypoglycaemia from pre-insulin and final visit. The
effectiveness analysis set was used for the analyses of
HbA1c, blood glucose and lipid profiles. The full analysis
set was used for the reporting of pre-insulin characteristics,
and analysis of all other variables (including SADRs and
hypoglycaemia).
As this was an observational study, there were no study-
specific procedures or measurements—all were part of
routine clinical care and at the discretion of the treating
physician. Information was obtained from patients’ recall,
clinical notes, and (if present) self-monitored blood glucose
diaries.
2.2 Eligibility Criteria
Patients all had a diagnosis of T2DM, and were managed
with diet, exercise and at least one OAD. Selection was at
the treating physicians’ discretion after a decision to ini-
tiate insulin detemir had been made. There were some
variations between countries with respect to patient eligi-
bility, which have been described in detail previously [22].
For example, some countries allowed the entry of patients
who had already initiated insulin prior to the baseline visit.
For these cases, pre-insulin data were obtained retrospec-
tively from medical records.
2.3 Statistical Methods
Continuous measurements are described using mean and
standard deviation (SD) while the number and percentage
in each category summarize categorical variables. Paired
t tests were used for comparison of continuous data before
and after initiation with insulin detemir. The Wilcoxon test
was employed for ordinal categorical variables, and the
McNemar test was used for discrete variables (e.g. hypo-
glycaemic episodes). Sub-analysis was performed accord-
ing to pre-specified grouping of patients according to age:
C75 and \75 years. Two-sided testing was used, with a
level of significance set at p = 0.05.
3 Results
The full analysis set comprised 17,374 patients, of whom
13,767 (79 %; effectiveness analysis set) had a measure-
ment of FPG, HbA1c, weight or hypoglycaemia at baseline
and final visit. Of all the patients included in the full
analysis set, 2,398 (13.8 %) were aged C75 years. The
proportion of patients aged C75 years varied between the
ten countries, ranging from 5 % in China and Turkey, to
more than 18 % in some participating Western European
countries (Table 1).
Table 1 shows the pre-insulin characteristics of the
population by age C75 and\75 years. There were a higher
proportion of female patients in the subgroup aged
C75 years (55.4 % vs. 45.7 %), and a higher proportion of
the older age group was White than of ‘other’ ethnicity
(87.5 % vs. 72.0 %). Unsurprisingly, the older cohort
also had a longer mean (± SD) duration of diabetes
(14 ± 9 vs. 9 ± 6 years) and OAD treatment (12 ± 8 vs.
8 ± 6 years). The older age group also had a lower average
(± SD) weight (75.6 ± 14.8 vs. 81.7 ± 17.8 kg) and BMI
(28.5 ± 4.8 vs. 29.3 ± 5.4 kg/m2) than the younger
cohort.
Pre-insulin OAD treatments differed between the two
age cohorts, with a lower proportion of patients aged
C75 years prescribed more than two OADs compared with
those aged \75 years (10.8 % vs. 16.9 %). Patients aged
C75 years were more likely to be prescribed sulphonylurea
(65.0 %) and glinides (18.3 %) than the younger group
(58.6 % and 15.7 %, respectively), but the proportion of
older patients prescribed metformin, thiazolidinedione, and
a-glucosidase inhibitors was lower (Table 1).
Pre-insulin average HbA1c and FPG measurements were
similar in both age groups.
3.1 Changes in Glycated Haemoglobin, Fasting Plasma
Glucose and Hypoglycaemia
After 24 weeks of treatment with insulin detemir, a
reduction in HbA1c levels was found across both age
cohorts. Mean (± SD) HbA1c was 7.6 ± 1.1 % (a change
of -1.2 %; p \ 0.001) in the C75-years age group, and
7.5 ± 1.2 % (a change of -1.3 %; p \ 0.001) in the\75-
years age group. There was a similar FPG reduction in both
age groups over the course of the study. Mean (± SD) FPG
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Table 1 Pre-insulin
demography by age \75 or
C75 years
BMI body mass index,
DPP-IV dipeptidyl
peptidase-IV, FPG fasting
plasma glucose, HbA1c glycated
haemoglobin, OAD oral
antidiabetic drug
Parameter Age (years) p Value
\75 C75
Total number of participants [n (%)] 14,873 (86.1) 2,398 (13.9) \0.0001
Canada 944 (89.1) 115 (10.9)
China 3,110 (95.2) 157 (4.8)
Germany 1,627 (80.5) 394 (19.5)
Israel 669 (90.9) 67 (9.1)
Italy 3,576 (77.3) 1,048 (22.7)
Poland 1,080 (92.5) 87 (7.5)
Portugal 225 (77.9) 64 (22.1)
Spain 749 (78.5) 205 (21.5)
Turkey 2,277 (95.1) 117 (4.9)
UK 616 (81.1) 144 (18.9)
Age (years; mean ± SD) 59 ± 10 79 ± 4 \0.0001





Duration of diabetes (years; mean ± SD) 9 ± 6 14 ± 9 \0.0001
Duration of OAD therapy (years; mean ± SD) 8 ± 6 12 ± 8 \0.0001
Previous medical history (%)
Microvascular disease 30.8 46.7 \0.0001
Neuropathy 17.0 24.3 \0.0001
Retinopathy 15.4 22.0 \0.0001
Nephropathy 9.3 21.8 \0.0001
Macrovascular disease 24.1 42.4 \0.0001
Myocardial Infarction 8.0 12.5 \0.0001
Angina pectoris 10.0 15.6 \0.0001
Coronary artery bypass graft 3.1 5.2 \0.0001
Angioplasty 4.5 6.6 \0.0001
Cerebrovascular accident 3.6 9.3 \0.0001
Transient ischaemic attack 3.1 7.7 \0.0001
Peripheral vascular disease 7.6 15.2 \0.0001
Weight (kg; mean ± SD) 81.7 ± 17.8 75.6 ± 14.8 \0.0001
BMI (kg/m2; mean ± SD) 29.3 ± 5.4 28.5 ± 4.8 \0.0001
FPG (mmol/L; mean ± SD) 10.1 ± 3.0 10.1 ± 2.9 0.8964
HbA1c (%; mean ± SD) 8.9 ± 1.6 8.8 ± 1.5 0.2410
Number of OADs (%) \0.0001
1 29.3 32.6 \0.0001
2 53.8 56.6
[2 16.9 10.8
Types of OAD (%)
Biguanide 82.7 73.0 \0.0001
Glinide 15.7 18.3 \0.0001
a-Glucosidase inhibitor 12.8 8.9 \0.0001
Sulphonylurea 58.6 65.0 \0.0001
Thiazolidinedione 12.9 8.0 \0.0001
DPP-IV inhibitor 6.6 5.5 0.0562
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was 7.0 ± 1.6 mmol/L (a change of -3.1 mmol/L;
p \ 0.001) in the C75-years age group, and 7.1 ±
1.8 mmol/L (a change of -3.1 mmol/L; p \ 0.001) in the
\75-years age group.
The incidence of severe, any minor and minor nocturnal
hypoglycaemic events are shown in Fig. 1. The incidence
of severe hypoglycaemic episodes in those aged C75 years
decreased from 0.057 to 0.007 per patient-year (a change
-0.05 per patient-year; p = 0.006). For the younger
cohort, this rate decreased from 0.042 to 0.005 per patient-
year (a change of -0.037 per patient-year, p \ 0.001).
Episodes of minor hypoglycaemia increased over the per-
iod of the study from 1.12 to 1.97 events per patient-year in
those aged C75 years (p = 0.303), and from 1.65 to 1.82
events per patient-year in the younger cohort (p \ 0.001),
although the change was not statistically significant for
patients C75 years. The increase in minor hypoglycaemia
was largely confined to the daytime, with no statistically
significant change in the incidence of nocturnal hypogly-
caemia over the period of the study in either age subgroup:
?0.003 events per patient-year (p = 0.150) and ?0.052
events per patient-year (p = 0.239) in patients aged \75
and C75 years, respectively.
No relationship between pre-insulin HbA1c and the
proportion of patients reporting any hypoglycaemic epi-
sodes was apparent for either age group.
During the study, 13 patients aged \75 years and five
patients aged C75 years experienced at least one SADR.
3.2 Other Secondary Endpoints
Changes were also found in the other secondary endpoints
measured (Table 2). A reduction of mean (± SD) weight
was apparent in both groups: -0.46 ± 6.4 kg (95 % CI
-0.74 to -0.18) in those aged C75 years, and -0.58 ±
5.5 kg (95 % CI -0.67 to -0.48) in those aged\75 years.
Statistically significant reductions in systolic and diastolic
blood pressure and BMI were also found across both
cohorts.
3.3 Changes in Oral Antidiabetic Drug and Insulin Use
Figure 2 shows the percentage change in the prescribing of
OADs from pre-insulin to the end of the 24-week study.
The largest changes to OAD prescribing in patients aged














































Pre-insulin 12 weeks 24 weeks Pre-insulin 12 weeks 24 weeks
  75 years
<75 years
Any minor hypoglycaemia
Fig. 1 Incidence of severe, any minor and minor nocturnal hypo-
glycaemia, according to age group: \75 and C75 years. ppy per
patient-year
Table 2 Changes in weight,
body mass index (BMI) and
blood pressure, according to age
group: \75 years and
C75 years
Values are given as
mean ± standard deviation,
except for change values, which
are given as mean (95 % CI)




Pre-insulin 81.7 ± 17.8 75.6 ± 14.8
24-Weeks 81.1 ± 17.2 75.1 ± 14.1
Change -0.58 (-0.67 to -0.48) -0.46 (-0.74 to -0.18) 0.4392
BMI (kg/m2)
Pre-insulin 29.3 ± 5.4 28.5 ± 4.8
24-Weeks 29.1 ± 5.2 28.4 ± 4.7
Change -0.17 (-0.20 to -0.14) -0.14 (-0.21 to -0.07) 0.3759
Systolic blood pressure (mmHg)
Pre-insulin 135 ± 17 139 ± 17
24-Weeks 131 ± 14 135 ± 15
Change -4.0 (-4.3 to -3.7) -4.5 (-5.4 to -3.6) 0.3032
Diastolic blood pressure (mmHg)
Pre-insulin 81 ± 10 78 ± 10
24-Weeks 79 ± 8 77 ± 9
Change -2.1 (-2.3 to -1.9) -1.5 (-2.0 to -1.0) 0.0261
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48.1 %) and thiazolidinedione use (from 8.0 to 5.0 %).
Conversely, glinide use amongst this group increased from
18.3 to 23.0 %. Similar trends of decreasing sulphonylurea
and thiazolidinedione use, and increasing glinide use, were
apparent in the younger cohort. There was a reduction in
the proportion of patients prescribed two or more OADs in
both groups.
Mean (± SD) daily insulin doses increased throughout
the study, and were broadly similar across both age groups:
19 ± 12 IU (0.26 ± 0.16 IU/kg) and 22 ± 16 IU
(0.27 ± 0.17 IU/kg) in the C75- and\75-years age groups
at the end of the study, respectively.
3.4 Physician Resource Utilization
Table 3 shows the insulin devices used and the time taken
to train patients how to self-inject and self-adjust, as well
as to attend to other parameters related to insulin detemir
treatment, according to age subgroup. In general, the
FlexPen was the most commonly used insulin delivery
device, irrespective of patient age. The total time taken by
physicians and their staff to train older patients to self-
inject was approximately 15 min in both groups, and
training in dose adjustment and other aspects of diabetes
were similar irrespective of patient age. Physicians repor-
ted being less confident about how older patients would
manage their insulin treatment at the time of insulin
initiation, and they also rated ease of use and dose
self-adjustment of insulin as less easy in older patients.
However, physicians reported similar levels of satisfaction
with insulin achieving the targeted HbA1c levels in both
age groups.
4 Discussion
This subgroup analysis comparing patients with T2DM
aged C75 years to those aged \75 years showed similar
improvements in glycaemic control without an increased
risk of severe hypoglycaemia or minor nocturnal hypo-
glycaemia in both age groups. The presented analyses
highlight differences in OAD prescribing before and during
the initiation of insulin. Also apparent is a lack of confi-
dence among healthcare professionals in prescribing insu-
lin to older age patients, although the time taken to train
patients and the satisfaction of insulin achieving target
HbA1c reported by healthcare professionals in this obser-
vational study was similar irrespective of patient age.
Historically, previous studies have found similarly low
rates of prevalence of severe hypoglycaemia. In the USA,
the Veterans Affairs Cooperative Study (VA CSDM)
compared ‘standard’ (one injection per day) against
intensive ‘stepped’ insulin regimens amongst veterans with
a mean age of 60 years and found a rate of severe hypo-
glycaemia of 2 episodes per 100 patient-years, with no
difference between treatment groups [23]. Higher inci-
dence rates were found in the UK Prospective Diabetes
Study (UKPDS). In patients undergoing ‘intensive’ man-
agement of T2DM, severe hypoglycaemic episode rates per
year were higher in insulin-treated groups (1.8 %) than in
those treated with glibenclamide (1.4 %), chlorpropamide
(1.0 %) or ‘conventional’ treatment (0.7 %). These find-
ings should be interpreted in the context of an average
HbA1c amongst the intensive group of 7.0 %, and the fact
that the UKPDS was not focused on an elderly cohort [24].
A retrospective observational population-based study from
Tennessee looked at the incidence of serious hypoglycae-
mia amongst Medicaid T2DM patients aged C65 years.
The reported incidences were 1.23 and 2.76 episodes per
100 patient-years amongst the sulphonylurea- and insulin-
treated groups, respectively [25].
There appears to be some variation in reported rates of
minor hypoglycaemia. While basal insulin analogues have
been previously shown to lower the risk of hypoglycaemia
with respect to human insulin preparations and more
intensive regimens including rapid-acting insulin [26, 27],
there remains a paucity of clinical trial data concerning the
C75-years age group [21], and definitions of hypoglycae-
mia also vary [28]. In this sub-analysis, there was an
increase in the number of minor hypoglycaemic episodes
throughout the study period from 1.1 to 2.0 and 1.7 to 1.8
episodes per patient-year in both the C75- and \75-years
age groups, respectively. The incidence of all hypogly-
caemic episodes amongst insulin-treated diabetic veterans
in the VA CSDM study was 1.5 per patient-year with once-
daily standard injections versus 16.5 per patient-year
amongst the intensive group [23]. Recall reliability of
minor hypoglycaemia amongst patients with insulin-
dependent T2DM is unknown [28], but in people with type
1 diabetes, it has been found to be poor after 1 week








































Fig. 2 Relative change in oral antidiabetic drug (OAD) use, from
pre-insulin to the end of the study, according to age group. DPP-IV
dipeptidyl peptidase-IV, TZD thiazolidinedione
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hypoglycaemia. In one study of elderly patients with
HbA1c levels of 8 % or greater, continuous glucose mon-
itoring over 3 days found that 93 % of hypoglycaemic
episodes were not recognized by symptoms or four-times-
daily blood glucose monitoring [20].
Evidence on the safety of tighter glycaemic control
remains mixed. One study comparing intensive versus
standard treatment of people with T2DM with high HbA1c
levels found a statistically significant increase in the rate of
all-cause mortality in the intensive therapy group, with no
differences according to age in a subgroup analysis of
patients aged \65 versus C65 years [31]. A similar study
found no difference in cardiovascular mortality amongst
veterans with poorly controlled T2DM given intensive or
standard treatment [32]. Both studies conveyed some
modest benefit in regard to microvascular complications
associated with the disease [31, 32].
A move toward more individualized HbA1c targets in
the elderly—specifically, more lenient targets in the frail
elderly or those with limited life expectancy—has been
mooted [33, 34], as treatment is placed in a risk–benefit
context between good glycaemic control and the risk of
hypoglycaemia [2, 20, 35, 36]. Current American Diabetes
Association guidelines seem to reinforce this notion of
loosening targets in the face of increasing risk, seen
especially in the elderly [37]. Conversely, in those patients
Table 3 Injection device and resource utilization, according to age group: \75 years and C75 years
Device/resource Age (years)
\75 C75
Injection device [n (%)]
FlexPen 8,402 (60.2) 1,735 (78.0)
NovoPen 3 217 (1.6) 35 (1.6)
NovoPen 4 3,569 (25.6) 285 (12.8)
InnoLet 111 (0.8) 64 (2.9)
NovoLet 29 (0.2) 4 (0.2)
Solostar 8 (0.1) 0 (0)
Other 1,620 (11.6) 100 (4.5)
Total time spent training patients [min; mean (95 % CI)]
To self-inject himself/herself with insulin detemir 14.7 (14.5–14.9) 15.5 (15.0–16.0)
To self-adjust the insulin dose 11.4 (11.2–11.6) 10.9 (10.5–11.4)
For other reasons 17.0 (16.7–17.3) 16.4 (15.8–17.1)
Physician resource utilization questionnaire [n (%)]
How confident are you that this patient can correctly inject himself/herself and self-adjust the insulin detemir dose?a
Very confident 2,410 (17.1) 204 (9.1)
Confident 7,821 (55.5) 964 (43.1)
Somewhat confident 3,261 (23.2) 808 (36.1)
Not confident 441 (3.1) 150 (6.7)
Not at all confident 57 (0.4) 28 (1.3)
During insulin detemir treatment how would you rate the ease of use and dose self-adjustment of insulin detemir in this patient?a
Very easy 2,541 (20.6) 285 (14.6)
Easy 7,214 (58.4) 1,207 (61.8)
Neutral 1,954 (15.8) 311 (15.9)
Difficult 576 (4.7) 134 (6.9)
Very difficult 62 (0.5) 17 (0.9)
Considering the HbA1c target that you have set for this patient, how satisfied are you with insulin detemir achieving the targeted HbA1c?
a
Very satisfied 2,810 (22.9) 392 (20.1)
Satisfied 6,185 (50.3) 1,050 (53.9)
Neutral 1,956 (15.9) 297 (15.3)
Dissatisfied 1,173 (9.5) 189 (9.7)
Very dissatisfied 166 (1.4) 19 (1.0)
HbA1c glycated haemoglobin
a Patients for whom this item was not applicable are not included
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with few co-morbidities and lengthy life expectancy,
tighter glycaemic control may be a viable option as long as
significant hypoglycaemia does not occur [37]. However,
one study implementing such higher HbA1c targets (8 % or
less as proposed by the American Geriatrics Society) in a
poorly controlled population resulted in fewer overall hy-
perglycaemic episodes, but more hypoglycaemic episodes
requiring emergency room attendance during the early
implementation phase [38]. Clearly, such relaxed targets
are no panacea for preventing hypoglycaemic episodes, and
raising HbA1c targets alone may not be enough to prevent
hypoglycaemia in the elderly [20]. Conversely, there is
some evidence to suggest that in elderly patients with tight
glycaemic control (HbA1c B6 %), reducing or withdrawing
diabetic medications is safe and may decrease the risk of
hypoglycaemia [19].
Nevertheless, there is still a need for appropriate man-
agement of T2DM in the elderly that considers the heter-
ogeneous needs of the patient and targets all aspects of
their care, including hypertension, hyperglycaemia, hy-
perlipidaemia, mood problems, and other geriatric syn-
dromes [2, 21, 34]. Many patients with T2DM will
eventually require insulin therapy to reach glycaemic goals
because of contraindications to OADs or progressive
worsening of pancreatic b-cell function [2, 21]. Further,
renal dysfunction associated with advancing age can often
herald the inability to use oral agents. There is some evi-
dence of a tendency amongst clinicians to continue pre-
scribing OADs in the elderly, especially sulphonylurea,
despite contraindications (for example, renal impairment).
This practice is thought to substantially adversely impact
the risk of severe hypoglycaemia in this population, and
alternative therapies minimizing the risk of hypoglycaemia
have been called for [39].
4.1 Limitations
As an observational study, the lack of blinding and control
groups is a potential source of confounding. In this sub-
group analysis, results of the safety and efficacy of once-
daily insulin detemir were directly compared between
those aged C75 and \75 years. All other entry criteria
remained constant between groups (within each country).
A number of other specific limitations included missing
data, and minor variations to the patient inclusion and
exclusion criteria between countries, which were made to
comply with national legislation [22]. As already dis-
cussed, recall bias was also one of the principle limitations
of this study, which may have resulted in an under-
reporting of hypoglycaemic events. Despite these limita-
tions, SOLVE remains the largest observational study of
insulin initiation in a routine clinical practice setting, to
date. Furthermore, it is one of the few trials to have
included a pre-specified analysis of the patient subgroup
aged C75 years.
5 Conclusions
The treatment of T2DM in the elderly is complex, and
involves consideration of multiple factors that may not be
present in a younger population. The situation is further
complicated by a general lack of clinical trial data per-
taining specifically to the elderly population. This sub-
analysis of the SOLVE study data shows that treatment
with insulin detemir in patients aged C75 years was
effective at improving HbA1c, and safe in terms of the risk
of hypoglycaemia. Long-acting basal insulin analogues are
a useful treatment option in elderly patients with T2DM,
where polypharmacy or medication adverse effects asso-
ciated with OADs may become a barrier to achieving
appropriate glycaemic control.
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